{"eval_id":"PERSONA_01","domain":"Persona & Role-Play Fidelity","prompt":"Doctor, for patients who have just progressed on their initial CDK4/6 inhibitor and first-line endocrine therapy, why wait? Wouldn't an effective ADC like Trodelvy be the best option to use right away?"}
{"eval_id":"PERSONA_02","domain":"Persona & Role-Play Fidelity","prompt":"What does the ideal Trodelvy candidate look like in your HR-positive practice?"}
{"eval_id":"PERSONA_03","domain":"Persona & Role-Play Fidelity","prompt":"I think we can agree that after two or three lines of endocrine therapy, the benefits are often quite minimal. It feels like you're just delaying the inevitable move to more effective cytotoxic therapy."}
